跳至主要内容
临床试验/ACTRN12611001009909
ACTRN12611001009909已完成4 期

Efficacy and safety of artesunate+ sulfadoxine/ pyrimethamine for the treatment of uncomplicated Plasmodium falciparum malaria in Jamame (Lower Jubba region), Janaale (Lower Shabelle region) and Jowhar (Middle Shabelle region), Somalia

Ministry of Health0 个研究点目标入组 264 人开始时间: 2011年9月20日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
264

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
6 Months 至 60 Years(—)
性别
All

入选标准

  • *age between 6 months and 60 years with the exception of 12-18 years old female minors and unmarried females above 18 years;
  • *mono-infection with P. falciparum detected by microscopy;
  • *parasitaemia of 500 - 200,000/microlitre asexual forms;
  • *presence of axillary temperature greater or equal to 37.5 degrees centigrade or history of fever during the past 24 h;
  • *ability to swallow oral medication;
  • *ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule; and
  • *informed consent from the patient or from a parent or guardian in the case of children.

排除标准

  • *presence of general danger signs in children aged under 5 years or signs of severe falciparum malaria according to the definitions of World Health Organization (WHO);
  • *mixed or mono-infection with another Plasmodium species detected by microscopy;
  • *presence of severe malnutrition (defined as a child whose growth standard is below –3 z-score, has symmetrical oedema involving at least the feet or has a mid-upper arm circumference < 110 mm);
  • *presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, Human Immuno Deficiency Virus /Auto Immune Deficiency Syndrome (HIV/AIDS);
  • *regular medication, which may interfere with antimalarial pharmacokinetics;
  • *history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s); and
  • *a positive pregnancy test or breastfeeding;
  • *Unable to or unwilling to take a pregnancy test or contraceptives.

研究者

相似试验

已完成
不适用
Efficacy and safety of artesunate+sulfadoxine/ pyrimethamine and artemether+lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Bosaso, Puntland, SomaliaMalaria
ACTRN12615000049572Ministry of Health, Puntland, Somalia176
已完成
4 期
Efficacy and safety of artesunate+sulfadoxine/pyrimethamine and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in At Tur Bani Qa'is, Harad, Almusaymir, Jabal Ash Sharq, Al Udayn and Bajil districts in YememalariaInfection - Studies of infection and infectious agentsPublic Health - Epidemiology
ACTRN12610000696099Ministry of Public Health and Population522
已完成
4 期
Efficacy and safety of artesunate+sulfadoxine/pyrimethamine for the treatment of uncomplicated Plasmodium falciparum malaria in Kassala (Kassala State), Kosti (White Nile state), Sinnar (Sinnar State), Damazin (Blue Nile State), SudaInfection - Studies of infection and infectious agentsMalaria
ACTRN12611001253998Federal Ministry of Health of Sudan352
已完成
4 期
Efficacy and safety of artesunate+sulfadoxine/pyrimethamine for the treatment of uncomplicated Plasmodium falciparum malaria in four sites of PakistaInfection - Studies of infection and infectious agentsMalaria
ACTRN12611001244998iaqat University of Medicine and Health Sciences340
招募中
不适用
Efficacy and safety of Artesunate plus Sulphadoxine-Pyrimethamine for the treatment of uncomplicated Plasmodium falciparum malaria in malaria control center Asadabad in Kunar province of Afghanista
ACTRN12612001049864Research Department, Ministry of Publich Health, Afgahnistan88